Udenafil

Udenafil
Clinical data
Routes of; administration	By mouth
ATC code	G04BE11 (WHO) ;
Legal status
Legal status	US: Not approved; In general: ℞ (Prescription only);
Pharmacokinetic data
Protein binding	93,9%
Metabolism	Liver (mainly CYP3A4)
Elimination half-life	7.3–12.1 hours
Excretion	Biliary
Identifiers
	IUPAC name 3-(1-Methyl-7-oxo-3-propyl-4,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide;
CAS Number	268203-93-6 ;
PubChem CID	6918523;
DrugBank	DB06267 ;
ChemSpider	5293720 ;
UNII	L5IB4XLY36;
KEGG	D10027 ;
CompTox Dashboard (EPA)	DTXSID00870301 ;
Chemical and physical data
Formula	C25H36N6O4S
Molar mass	516.66 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2\N=C(/Nc1c(nn(c12)C)CCC)c3cc(ccc3OCCC)S(=O)(=O)NCCC4N(C)CCC4;
	InChI InChI=1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32) ; Key:IYFNEFQTYQPVOC-UHFFFAOYSA-N ;
	(what is this?) (verify)

The drug udenafil is marketed under the trade name Zydena. It is within the PDE₅ inhibitor class (which also includes avanafil, sildenafil, tadalafil, and vardenafil). Like other PDE₅ inhibitors, it is used to treat erectile dysfunction. Udenafil was developed by Dong-A Pharmaceutical.^[1] It has fairly rapid onset of action (peak plasma concentration after 1 to 1.5 hours), and has long duration of action (plasma half-life of 11 to 13 hours). Udenafil's pharmacokinetics allows once-daily dosage (in addition to on-demand use).^[2] Typical doses are 100 and 200 mg. Udenafil is available in Korea, Russia, and the Philippines.^[3] It has not yet been approved for use in the United States by the U.S. Food and Drug Administration.

References

^ Zydena (udenafil) product-information page. Dong-A Pharmaceutical. Retrieved on April 13, 2009.
^ Kang SG, Kim JJ (April 2013). "Udenafil: efficacy and tolerability in the management of erectile dysfunction". Therapeutic Advances in Urology. 5 (2): 101–10. doi:10.1177/1756287212470019. PMC 3607490. PMID 23554845.
^ "Zydena". Drugs.com.

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

[1] Zydena (udenafil) product-information page. Dong-A Pharmaceutical. Retrieved on April 13, 2009.

[2] Kang SG, Kim JJ (April 2013). "Udenafil: efficacy and tolerability in the management of erectile dysfunction". Therapeutic Advances in Urology. 5 (2): 101–10. doi:10.1177/1756287212470019. PMC 3607490. PMID 23554845.

[3] "Zydena". Drugs.com.

[1]

[2]

[3]

Clinical data

Routes of administration	By mouth
ATC code	G04BE11 (WHO)
Legal status
Legal status	US: Not approved In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding	93,9%
Metabolism	Liver (mainly CYP3A4)
Elimination half-life	7.3–12.1 hours
Excretion	Biliary
Identifiers
IUPAC name 3-(1-Methyl-7-oxo-3-propyl-4,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide
CAS Number	268203-93-6^N
PubChem CID	6918523
DrugBank	DB06267^Y
ChemSpider	5293720^Y
UNII	L5IB4XLY36
KEGG	D10027^N
CompTox Dashboard (EPA)	DTXSID00870301
Chemical and physical data
Formula	C₂₅H₃₆N₆O₄S
Molar mass	516.66 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES O=C2\N=C(/Nc1c(nn(c12)C)CCC)c3cc(ccc3OCCC)S(=O)(=O)NCCC4N(C)CCC4
InChI InChI=1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32)^Y Key:IYFNEFQTYQPVOC-UHFFFAOYSA-N^Y
^NY (what is this?) (verify)